Article

Research collaboration to investigate new treatments for AMD

Berlin, Germany-Jerini AG's U.S. subsidiary, Jerini Ophthalmic Inc., signed a research collaboration agreement with University College London (UCL) Institute of Ophthalmology to investigate the pathobiology of age-related macular degeneration (AMD).

Berlin, Germany-Jerini AG's U.S. subsidiary, Jerini Ophthalmic Inc., signed a research collaboration agreement with University College London (UCL) Institute of Ophthalmology to investigate the pathobiology of age-related macular degeneration (AMD).

Two of Jenrini Ophthalmic's leading drug candidates, JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of the component cascade will be tested.

The projects will collaborate with UCL's new Translational Vision Research Laboratory, headed by David T. Shima, PhD, recently appointed Rothes professor at UCL and chief scientific officer for Jenrini Ophthalmic.

"Our collaboration with David Shima and UCL gives Jerini Ophthalmic access to the best resources and expertise available in the field of ophthalmology," said Anthony P. Adamis, chief executive officer and president of Jerini Ophthalmic. "Working closely with the exceptional UCL research infrastructure will enable us to optimally develop and advance our ophthalmology drug candidates."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.